APC-Linked Monoclonal Antibody to Chemerin (CHEM)
Code | Size | Price |
---|
LAA945Hu54-100ul | 100ul | £282.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum order quantity: 2 |
Quantity:
LAA945Hu54-200ul | 200ul | £390.00 |
Quantity:
LAA945Hu54-1ml | 1ml | £930.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Guinea Pig
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
TIG2; RARRES2; Tazarotene-Induced Gene 2; Retinoic Acid Receptor Responder 2,Tazarotene Induced; RAR-responsive protein TIG2
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Ig Isotype:
IgG1 Kappa
Immunogen:
RPA945Hu01-Recombinant Chemerin (CHEM)
Item Name:
Chemerin
Potency (Clone Number):
E1
Reactivity:
Po;
Source:
Antibody labeling
Subcategory:
Antibody labeling
USAGE:
Western blotting: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Monoclonal Antibody to Chemerin (CHEM) | MAA945Hu22 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||